Prospect of Trump tariff casts pall over U.S. solar industry
LOS ANGELES (Reuters) – U.S. solar companies are snapping up cheap imported solar panels ahead of a trade decision by the Trump administration that could drive up costs and cloud the fortunes of one of the economy’s brightest stars.
Citigroup sets higher profit targets at first investor day since crisis
NEW YORK (Reuters) – Citigroup Inc issued loftier projections for its long-term profitability on Tuesday at the first major conference it has held for its own investors in more than nine years.
Activist investor Sandell presses for Barnes & Noble sale: WSJ
(Reuters) – Activist investor Sandell Asset Management Corp wants Barnes & Noble to try to sell itself again, saying the bookstore chain will benefit from a new owner, the Wall Street Journal reported on Monday.
VW chief raps Porsche labor boss in Heilbronner Stimme interview
BERLIN (Reuters) – Volkswagen CEO Matthias Mueller strongly criticized Porsche’s labor chief in German daily Heilbronner Stimme on Tuesday over public remarks about Audi’s management, in a sign of growing tensions within the automotive group.
Fed and Trump keep dollar glum as Greece warms Europe
LONDON (Reuters) – The dollar sat at a more-than-one-year low while stocks climbed on Tuesday, as investors bet that subdued U.S. inflation and strains in Washington would limit Federal Reserve interest rate moves for the rest of the year.
Oil extends gains as Saudi pledges export curbs
TOKYO (Reuters) – Oil prices extended gains on Tuesday after Saudi Arabia pledged to curb exports from next month and OPEC called on several members to boost compliance with output cuts to help rein in oversupply and tackle flagging prices.
Qualcomm accuses tech group of ‘misdirecting’ trade regulators
(Reuters) – Qualcomm Inc fired back in its case against Apple Inc on Monday, accusing its critics of waging a “coordinated effort aimed at misdirecting” trade regulators.
‘Pharma bro’ Shkreli says he will not testify in securities fraud trial
(Reuters) – Martin Shkreli, the pharmaceutical entrepreneur vilified as the “pharma bro” for raising the price of a life-saving drug by 5,000 percent, said on Monday in federal court that he would not testify in his securities fraud trial.
After $50 billion deal spree, China’s HNA moves to clear ownership concerns
LONDON (Reuters) – Chinese conglomerate HNA Group has pushed back against media reports that it faces mounting pressure from bankers and regulators, even as it announced a shareholding shake-up in a bid to quash concerns over its ownership.
Exclusive: Goldman Sachs retreats from ETF lead market making
NEW YORK (Reuters) – Goldman Sachs Group Inc is pulling back substantially from trading that helps backstop the fast-growing use of U.S. exchange-traded funds, giving smaller firms an opportunity to grab market share.
